AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

United States Overactive Bladder (Anticholinergics & Beta Adrenoreceptor Agonists) Market Insights, Trends and Forecasts, 2019-2021 & 2031 - ResearchAndMarkets.com

November 8, 2019 GMT

DUBLIN--(BUSINESS WIRE)--Nov 8, 2019--

The “US Overactive Bladder (Anticholinergics & Beta Adrenoreceptor Agonists) Market Report: Insights, Trends and Forecast (2021-2031)” report has been added to ResearchAndMarkets.com’s offering.

The U.S. OAB market is estimated to reach US$3.49 billion in 2031, growing at a CAGR of 5.01%, for the period spanning from 2021-2031.

The factors such as rising ageing population, increasing healthcare expenditure, growing obese population, surging diabetic prevalence, increasing coffee consumption and accelerating economic growth are expected to drive the market growth.

However, the growth of the industry would be challenged by entry of generic drugs, stringent regulations, associated business risk and side effects of oral therapies. A few notable trends include advancing innovative therapies, rising awareness of overactive bladder, growing adoption of procedural (third line) therapy, development of gene therapy and progressing drug pipeline.

The three main treatment approaches for the treatment of overactive bladder are behavioural therapy (Bladder Training & Pelvic Floor Exercises), prescription therapy (Oral Anticholinergics & 3 Adrenoreceptor Agonist) and procedural therapy (BOTOX & Neuromodulation).

The fastest-growing market is the U.S. owing to continuous advancement in 3 Adrenoreceptor Agonist drugs, increasing OAB population and growing research & development efforts by domestic pharmaceutical firms to launch novel drugs with innovative mechanism of actions drugs.

Scope of the report:

Key Topics Covered:

1. Market Overview

1.1 Overactive Bladder

1.2 Symptoms & Diagnosis

1.3 Treatment

1.4 Overactive Bladder with BPH

2. The U.S. Market Analysis

2.1 Overactive Bladder Market

2.1.1 The U.S. Overactive Bladder Market Value Forecast

2.1.2 The U.S. Overactive Bladder Market Value by Drug Class

2.1.3 The U.S. Anticholinergics Market Value Forecast

2.1.4 The U.S. 3 Adrenoreceptor Agonists Market Value Forecast

2.1.5 The U.S. 3 Adrenoreceptor Agonists Market Value by Drug Type

2.1.6 The U.S. Vibegron Drug Revenue Forecast

2.1.7 The U.S. Overactive Bladder Patient Population Forecast

2.1.8 The U.S. Overactive Bladder Treated Patient Population Forecast

2.1.9 The U.S. Overactive Bladder Prescriptions Forecast

2.1.10 The U.S. Vibegron Drug Prescriptions Forecast

2.1.11 The U.S. Mirabegron Drug Prescriptions Forecast

2.2 Overactive Bladder Market with BPH

2.2.1 The U.S. Overactive Bladder with BPH Patient Population Forecast

2.2.2 The U.S. 3 Adrenoreceptor Agonist Market by Penetration Rate

2.2.3 The U.S. 3 Adrenoreceptor Agonist Patient Penetration by Drug

2.2.4 The U.S. Vibegron Drug Revenue Forecast

2.2.5 The U.S. Vibegron Prescriptions Forecast

2.2.6 The U.S. Mirabegron Prescriptions Forecast

3. Market Dynamics

3.1 Growth Drivers

3.1.1 Rising Ageing Population

3.1.2 Increasing HealthCare Expenditure

3.1.3 Growing Obese Population

3.1.4 Surging Diabetic Prevalence

3.1.5 Increasing Coffee Consumption

3.1.6 Accelerating Economic Growth

3.2 Key Trends and Developments

3.2.1 Advancing Innovative Therapies

3.2.2 Rising Awareness of Overactive Bladder

3.2.3 Growing Adoption of Procedural (Third Line) Therapy

3.2.4 Development of Gene Therapy

3.2.5 Progressing Drug Pipeline

3.3 Challenges

3.3.1 Entry of Generic Drugs

3.3.2 Stringent Regulations

3.3.3 Associated Business Risk

3.3.4 Side Effects of Oral Therapies

4. Competitive Landscape

4.1 Global OAB Market

4.1.1 Key Players - Revenue Comparison

4.1.2 Key Players - Market Cap Comparison

4.1.3 Key Players - Research & Development Expenditure Comparison

5. Company Profiles

5.1 Allergan Plc

5.1.1 Business Overview

5.1.2 Financial Overview

5.1.3 Business Strategies

5.2 Pfizer Inc.

5.3 Astellas Pharma Inc.

5.4 Hisamitsu Pharmaceutical Co., Inc.

5.5 Medtronic Plc

5.6 Sumitomo Chemical Co., Ltd. (Urovant Sciences Ltd.)

For more information about this report visit https://www.researchandmarkets.com/r/t6ixs5

View source version on businesswire.com:https://www.businesswire.com/news/home/20191108005326/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD: UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: GENERAL HEALTH PHARMACEUTICAL HEALTH

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 11/08/2019 09:18 AM/DISC: 11/08/2019 09:18 AM

http://www.businesswire.com/news/home/20191108005326/en